RAD140
RAD140 is an investigational selective androgen receptor modulator devoloped as a future substitute of exogenous Testosterone replacement therapy. Some of the benefits under investigation are for the treatment of conditions such as muscle wasting and skeleton wasting, caused by breast cancer, RAD140 is currently under development by Radius Health, Inc..
In early 2020 a case report of drug-induced liver injury following use of RAD 140 was published. This report has reignited fears about the safety of SARMs being used without medical supervision or advice, including RAD 140. RAD 140 is still is in the first stage of clinical trials with the results expected in late 2020. When released these trials will share the safety, toxicity and potential adverse effects of RAD 140.Animal studies
According to a study conducted by researchers at the University of Southern California, Los Angeles, RAD 140 appears to be safer than testosterone replacement therapy in rats. Further research is required to determine if RAD 140 is also safer than TRT in human subjects.
Another study conducted in February 2011 found that RAD 140 slightly increased lean muscle mass when used in primate subjects, by targeting androgen receptors in skeletal tissue. These measured increases in lean muscle mass were not statistically significant, however, this may be due to the small group sizes and relatively large standard deviations.
